FDA Approval Summary: Abemaciclib With Endocrine Therapy for High-Risk Early Breast Cancer
PURPOSE: The US Food and Drug Administration approved abemaciclib in combination with endocrine therapy (ET) for the adjuvant treatment of adult patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative, node-positive, early breast cancer (EBC) at high risk of recurr...
Main Authors: | Amiri-Kordestani, L. (Author), Beaver, J.A (Author), Bloomquist, E. (Author), Ghosh, S. (Author), Kalavar, S. (Author), Mixter, B.D (Author), Mulkey, F. (Author), Osgood, C. (Author), Pazdur, R. (Author), Philip, R. (Author), Pierce, W.F (Author), Rizvi, F. (Author), Roy, A. (Author), Royce, M. (Author), Tang, S. (Author) |
---|---|
Format: | Article |
Language: | English |
Published: |
NLM (Medline)
2022
|
Subjects: | |
Online Access: | View Fulltext in Publisher |
Similar Items
-
Association between Ki-67 expression and clinicopathological features in prognosis of breast cancer: A retrospective cohort study
by: Hosein Kamranzadeh, et al.
Published: (2019-01-01) -
A Study on the Prognostic Factors of Breast Cancer Survival Time Using Bayesian Cox Model
by: Hossein Falahzadeh, et al.
Published: (2018-04-01) -
Inverse correlation between Ki67 expression as a continuous variable and outcomes in luminal HER2-negative breast cancer
by: Kaori Ushimado, et al.
Published: (2019-08-01) -
Análise das características clinicopatológicas, proliferação celular e alterações de número de cópias e metilação de genes supressores de tumor em carcinoma ex-adenoma pleomorfo
by: Mariano, Fernanda Viviane, 1984-
Published: (2009) -
Ki-67 expression as an indicator of invasiveness in patients with breast cancer
by: Ahmed Salah Mahdi, et al.
Published: (2018-01-01)